Prime Medicine Inc. (PRME)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Prime Medicine: Soon In The Clinic
Prime Medicine trades at a $548M valuation, significantly undervaluing its broad, potentially best-in-class gene-editing pipeline. PRME's therapies target five indications across liver, lung, and immunology/oncology, with leading preclinical efficacy and multi-billion-dollar addressable markets. Recent IND/CTA clearances, RMAT designation, and patent wins highlight PRME's clinical and strategic momentum despite a 54% stock decline from 52-week highs.
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.24 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.41 per share a year ago.
Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Prime Medicine, Inc. (PRME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Prime Medicine Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 382 | $1,090.48 | $1,115.44 | $24.96 | 2.29% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 87,310 | $322,170 | $268,914.8 | -$53,255.2 | -16.53% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 78 | $272.4 | $254.28 | -$18.12 | -6.65% |
 Farallon Capital Farallon Capital Management LLC | 1.24M | $6.87M | $3.83M | -$3.04M | -44.22% |
| NA Nizar Araji National Bank Of Canada /FI/ | 42 | $153.84 | $129.36 | -$24.48 | -15.91% |
Prime Medicine Inc. (PRME) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Prime Medicine Inc. ever had a stock split?
Prime Medicine Inc. Profile
| Biotechnology Industry | Healthcare Sector | Allan Reine CEO | NASDAQ (NMS) Exchange | 74168J101 CUSIP |
| US Country | 146 Employees | - Last Dividend | - Last Split | 20 Oct 2022 IPO Date |
Overview
Prime Medicine, Inc. is a biotechnology enterprise specialized in pioneering genetic therapies to combat a broad spectrum of diseases by harnessing the power of gene editing technology. Established in 2019, the company positions itself at the forefront of genetic medicine with its innovative approach to editing DNA sequences. Operating from its headquarters in Cambridge, Massachusetts, Prime Medicine is dedicated to realizing the potential of genetic correction and modification to treat conditions that have long been considered untreatable. The company has embarked on a significant collaboration with Cimeio Therapeutics, focusing on the development of Prime Edited Shielded-Cell & Immunotherapy Pairs, targeting genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome.
Products and Services
- Prime Editors
- Collaborative Research Projects
At the core of Prime Medicine's offerings are the Prime Editors, a revolutionary gene editing tool. This technology combines a Prime Editor protein, which is a fusion of a Cas protein and a reverse transcriptase enzyme, with a pegRNA (prime editing guide RNA). The pegRNA is crucial as it not only directs the Prime Editor to a specific location within the genome but also supplies the template needed for executing the desired edit on the target DNA sequence. This sophisticated mechanism allows for precision in gene editing, paving the way for treatment strategies that could correct genetic mutations at their source.
Underpinning Prime Medicine's innovative technology is its strategic research collaboration with Cimeio Therapeutics. This partnership is primarily focused on the development of Prime Edited Shielded-Cell & Immunotherapy Pairs. These novel therapeutic strategies are designed to treat a range of conditions, from genetic diseases to cancers like acute myeloid leukemia and myelodysplastic syndrome. This collaboration highlights Prime Medicine's commitment to leveraging its technology in concert with other biotech entities to address complex medical challenges.
